Top Markets
#1 Useless Coin Useless Coin +41.99%
#2 StonkBroker StonkBroker +40.52%
#3 Merlin's Seal BTC Merlin's Seal BTC +37.86%
#4 0G 0G +33.36%
#5 SAFEcoin SAFEcoin +30.76%
#6 Zora Zora +23.17%
#7 Dogs Dogs +22.42%
#8 Full Moon Full Moon +19.59%
#9 ADO Protocol ADO Protocol +15.93%
#10 rsERG rsERG +15.87%
Coin of the day
Useless Coin Useless Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Evommune, Inc. Evommune, Inc.

Evommune, Inc.

EVMN
Rank in Stocks #13758
Evommune, Inc. is a United States-based clinical-stage biotechnology company... Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Share Price
$12.78
Market Cap
$463.81M
Change (1 day)
-2.07%
Change (1 year)
-
Country
US
Trade Evommune, Inc. (EVMN)

Category

Healthcare
Revenue for Evommune, Inc. (EVMN)
Revenue in Aug 2026 TTM: 0
According to Evommune, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Evommune, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH